Research and Markets has announced the addition of the "Nuclear Receptor ROR Gamma - Pipeline Review, H2 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Nuclear Receptor ROR Gamma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nuclear Receptor ROR Gamma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • AbbVie Inc
  • Advinus Therapeutics Ltd
  • Arrien Pharmaceuticals, LLC
  • Aurigene Discovery Technologies Limited
  • Beijing Hanmi Pharmaceutical Co., Ltd.
  • Biogen Inc
  • Brickell Biotech, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Genentech, Inc.
  • Genfit SA
  • GlaxoSmithKline Plc
  • Japan Tobacco Inc.
  • Lead Pharma Holding B.V.
  • Nuevolution AB
  • Pfizer Inc.
  • Phenex Pharmaceuticals AG
  • Reata Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Visionary Pharmaceuticals, Inc.
  • Vitae Pharmaceuticals, Inc.

Key Topics Covered:

  1. Introduction
  2. Nuclear Receptor ROR Gamma Overview
  3. Therapeutics Development
  4. Pipeline Products for Nuclear Receptor ROR Gamma - Overview
  5. Pipeline Products for Nuclear Receptor ROR Gamma - Comparative Analysis
  6. Nuclear Receptor ROR Gamma - Therapeutics under Development by Companies
  7. Nuclear Receptor ROR Gamma - Therapeutics under Investigation by Universities/Institutes
  8. Nuclear Receptor ROR Gamma - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Nuclear Receptor ROR Gamma - Products under Development by Companies
  13. Nuclear Receptor ROR Gamma - Products under Investigation by Universities/Institutes
  14. Nuclear Receptor ROR Gamma - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/7s4q9f/nuclear_receptor

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Related Topics: Immune Disorders Drugs